Welcome to our dedicated page for LONA news (Ticker: LONA), a resource for investors and traders seeking the latest updates and insights on LONA stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect LONA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of LONA's position in the market.
Athira Pharma (NASDAQ: ATHA) changed its name to LeonaBio and will trade under new ticker LONA beginning January 12, 2026.
The name change follows a transformative exclusive license for lasofoxifene (Phase 3 ELAINE-3, >50% enrolled; topline data expected mid-2027) and an upfront private placement of $90 million plus warrants that could provide up to $146 million if fully exercised to fund development through key milestones into 2028.
